Finance

Lists
Why is 950210 up 2,52%?
Dive Deeper
950210:KRX
Prestige Biopharma Ltd
5 690,00 KRW
+2,52%
(+140,00) 1D
16 ოქტ, 15:30:30 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 950210...
Open
5 370 KRW
High
5 770 KRW
Low
5 370 KRW
Mkt. cap
341,95 მლრ.
Avg. vol.
33,56 ათ.
Volume
0,00
52-wk high
14 120 KRW
52-wk low
4 945 KRW
EPS
-896 KRW
Shares outstanding
60,10 მლნ.
No. of employees
64
Open
5 370 KRW
High
5 770 KRW
Low
5 370 KRW
Mkt. cap
341,95 მლრ.
Avg. vol.
33,56 ათ.
Volume
0,00
52-wk high
14 120 KRW
52-wk low
4 945 KRW
EPS
-896 KRW
Shares outstanding
60,10 მლნ.
No. of employees
64
News stories
From web sources and news partners
About Prestige Biopharma Ltd
CEO-
Employees64
Founded2015
Headquarters-
Sector-
Websiteprestigebiopharma.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
2,36 მლრდ.
7,81 მლრდ.
509,20 მლნ.
15,39 მლრდ.
Cost of goods sold
2,23 მლრდ.
10,17 მლრდ.
12,23 მლრდ.
17,68 მლრდ.
Cost of revenue
2,23 მლრდ.
10,17 მლრდ.
12,23 მლრდ.
17,68 მლრდ.
Research and development expenses
-
-
-
42,51 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24,95 მლრდ.
16,79 მლრდ.
14,63 მლრდ.
-36,73 მლრდ.
Operating expense
24,95 მლრდ.
16,79 მლრდ.
14,63 მლრდ.
20,81 მლრდ.
Total operating expenses
27,18 მლრდ.
26,96 მლრდ.
26,86 მლრდ.
38,49 მლრდ.
Operating income
-24,82 მლრდ.
-19,15 მლრდ.
-26,35 მლრდ.
-23,10 მლრდ.
Other non operating income
4,06 მლრდ.
-1,38 მლრდ.
-3,05 მლრდ.
7,24 მლრდ.
EBT including unusual items
-20,76 მლრდ.
-20,53 მლრდ.
-29,40 მლრდ.
-52,36 მლრდ.
EBT excluding unusual items
-20,76 მლრდ.
-20,53 მლრდ.
-29,40 მლრდ.
-23,56 მლრდ.
Income tax expense
-69,96 მლნ.
-17,84 მლნ.
-20,29 მლნ.
-43,51 მლნ.
Effective tax rate
0,34%
0,09%
0,07%
0,08%
Other operating expenses
-
-
-
573,69 მლნ.
Net income
-12,62 მლრდ.
-15,37 მლრდ.
-20,56 მლრდ.
-42,95 მლრდ.
Net profit margin
-534,55%
-196,66%
-4 037,83%
-279,14%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
3,62 მლრდ.
Interest expense
-
-
-
-6,92 მლრდ.
Net interest expenses
-
-
-
-3,31 მლრდ.
Depreciation and amortization charges
-
-
-
6,52 მლრდ.
EBITDA
-19,37 მლრდ.
-13,70 მლრდ.
-20,90 მლრდ.
-14,91 მლრდ.
Gain or loss from assets sale
-
-
-
-6,37 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები